Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$3.7 million.

  • Capricor Therapeutics' Net Cash Flow fell 10646.71% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.9 million, marking a year-over-year decrease of 18227.78%. This contributed to the annual value of -$3.4 million for FY2024, which is 16693.08% down from last year.
  • Latest data reveals that Capricor Therapeutics reported Net Cash Flow of -$3.7 million as of Q3 2025, which was down 10646.71% from -$5.6 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Net Cash Flow peaked at $57.7 million during Q3 2024, and registered a low of -$57.1 million during Q4 2024.
  • In the last 5 years, Capricor Therapeutics' Net Cash Flow had a median value of -$768395.0 in 2023 and averaged -$692394.3.
  • Examining YoY changes over the last 5 years, Capricor Therapeutics' Net Cash Flow showed a top increase of 686731.26% in 2024 and a maximum decrease of 109979.87% in 2024.
  • Capricor Therapeutics' Net Cash Flow (Quarter) stood at -$6.0 million in 2021, then skyrocketed by 119.98% to $1.2 million in 2022, then surged by 380.01% to $5.7 million in 2023, then crashed by 1099.8% to -$57.1 million in 2024, then soared by 93.47% to -$3.7 million in 2025.
  • Its last three reported values are -$3.7 million in Q3 2025, -$5.6 million for Q2 2025, and $17.5 million during Q1 2025.